Keith W. Marshall Sells 5,000 Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX) Stock

Prometheus Biosciences, Inc. (NASDAQ:RXDXGet Rating) CFO Keith W. Marshall sold 5,000 shares of Prometheus Biosciences stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $119.00, for a total transaction of $595,000.00. Following the completion of the sale, the chief financial officer now directly owns 9,811 shares in the company, valued at approximately $1,167,509. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Prometheus Biosciences Stock Down 2.5 %

Shares of RXDX opened at $115.00 on Friday. The firm has a market cap of $4.82 billion, a P/E ratio of -34.33 and a beta of -0.48. Prometheus Biosciences, Inc. has a 12-month low of $21.50 and a 12-month high of $122.75. The company’s 50-day moving average price is $87.83 and its 200 day moving average price is $61.97. The company has a current ratio of 11.19, a quick ratio of 11.19 and a debt-to-equity ratio of 0.11.

Prometheus Biosciences (NASDAQ:RXDXGet Rating) last issued its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.01). The company had revenue of $0.97 million during the quarter, compared to analysts’ expectations of $0.77 million. Prometheus Biosciences had a negative net margin of 1,847.71% and a negative return on equity of 61.37%. On average, sell-side analysts forecast that Prometheus Biosciences, Inc. will post -3.43 earnings per share for the current year.

Analysts Set New Price Targets

RXDX has been the topic of several recent research reports. Piper Sandler lifted their target price on shares of Prometheus Biosciences from $67.00 to $114.00 in a research note on Wednesday, December 7th. Credit Suisse Group lifted their target price on shares of Prometheus Biosciences from $59.00 to $142.00 and gave the stock an “outperform” rating in a research note on Thursday, December 8th. Stifel Nicolaus lifted their target price on shares of Prometheus Biosciences from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, November 1st. Oppenheimer lifted their target price on shares of Prometheus Biosciences from $61.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, December 8th. Finally, BTIG Research lifted their price target on Prometheus Biosciences from $74.00 to $181.00 and gave the stock a “buy” rating in a report on Thursday, December 8th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $107.80.

Institutional Trading of Prometheus Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of RXDX. Swiss National Bank raised its holdings in Prometheus Biosciences by 7.4% in the 1st quarter. Swiss National Bank now owns 27,600 shares of the biopharmaceutical company’s stock valued at $1,042,000 after buying an additional 1,900 shares during the period. JPMorgan Chase & Co. grew its position in Prometheus Biosciences by 454.6% in the 1st quarter. JPMorgan Chase & Co. now owns 82,927 shares of the biopharmaceutical company’s stock valued at $3,131,000 after acquiring an additional 67,975 shares in the last quarter. Bank of New York Mellon Corp grew its position in Prometheus Biosciences by 10.1% in the 1st quarter. Bank of New York Mellon Corp now owns 128,626 shares of the biopharmaceutical company’s stock valued at $4,857,000 after acquiring an additional 11,844 shares in the last quarter. MetLife Investment Management LLC grew its position in Prometheus Biosciences by 55.4% in the 1st quarter. MetLife Investment Management LLC now owns 17,464 shares of the biopharmaceutical company’s stock valued at $659,000 after acquiring an additional 6,227 shares in the last quarter. Finally, Rhumbline Advisers grew its position in Prometheus Biosciences by 3.4% in the 1st quarter. Rhumbline Advisers now owns 37,177 shares of the biopharmaceutical company’s stock valued at $1,404,000 after acquiring an additional 1,226 shares in the last quarter. 78.31% of the stock is currently owned by hedge funds and other institutional investors.

Prometheus Biosciences Company Profile

(Get Rating)

Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.

See Also

Receive News & Ratings for Prometheus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometheus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.